Company Profiles

driven by the PitchBook Platform

Celentyx

Description

Developer of healthcare platform designed to understand the effect of small molecule and biological candidate upon the human immune system. The company's ImmuKnowlogy platform allows rapid analysis of drug action on human immune cells and supports early progression of immuno-oncology therapies, enabling physicians to detect human system at the highest levels of resolution.

PRIVATE

Status

11-50

Employees

Early Stage VC

Latest Deal Type

$121k

Latest Deal Amount

$121k

Total Amount Raised

3

Investors

Description

Developer of healthcare platform designed to understand the effect of small molecule and biological candidate upon the human immune system. The company's ImmuKnowlogy platform allows rapid analysis of drug action on human immune cells and supports early progression of immuno-oncology therapies, enabling physicians to detect human system at the highest levels of resolution.

Website:

www.celentyx.com

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Biotechnology

Other Industries

Drug Discovery

Primary Office

Birmingham Research Park Vincent Drive, Edgbaston Birmingham B15 2SQEngland +44 (0)12 1414 8199
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Celentyx's full profile, request a free trial.

Celentyx Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Celentyx Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

Celentyx Investors (3)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
Mercia TechnologiesVenture CapitalMinority000 0000000 0000
Spinner Matched Investment FundOtherMinority000 0000000 0000
West Midlands EnterpriseVenture CapitalMinority000 0000000 0000
Mercia Technologies Venture Capital
Spinner Matched Investment Fund Other
West Midlands Enterprise Venture Capital

Celentyx Executive Team (5)

NameTitleBoard
Seat
Contact
Info
Nicholas Barnes Ph.DCo-Founder, Chief Executive Officer & Board Member
Catherine BradyChief Operating Officer
John CurnowChief Technology Officer
John GordonCo-Founder, Chief Scientific Officer & Board Member
Matthew Baker Ph.DVice President, Immunology and Oncology
Nicholas Barnes Ph.D Co-Founder, Chief Executive Officer & Board Member
Catherine Brady Chief Operating Officer
John Curnow Chief Technology Officer
John Gordon Co-Founder, Chief Scientific Officer & Board Member
Matthew Baker Ph.D Vice President, Immunology and Oncology

Celentyx Board Members (3)

NameRepresentingRoleSinceContact
Info
Alan Boyd MDSelfBoard Member000 0000
Mark Payton Ph.DMercia TechnologiesCo-Founder & Chief Executive Officer000 0000
Stephen Ellis Ph.DCelentyxBoard Observer000 0000
Alan Boyd MD Board Member Self
Mark Payton Ph.D Co-Founder & Chief Executive Officer Mercia Technologies
Stephen Ellis Ph.D Board Observer Celentyx
Request full access to PitchBook